

between SEF and SEE. Predictors of change over time including age, clinical and psychological factors, were examined using multiple regression and the population average GEE model.

Results: At baseline, 2087 women completed the SEF items, of whom 56% reported that they lacked interest in sex, and 40.6% women were sexually active. SEF and SEE were correlated over all time points ($r = 0.5-0.66$) but SEE scores were generally low. Proportions of women reporting 'a little', 'quite a bit' or 'very much' SEE were 34%, 39% and 22% respectively. Older age, CT and HADS anxiety and depression were significantly associated with worse baseline SEF/SEE with no effect of type of surgery, time since surgery, endocrine therapy or body image (BI). SEF improved significantly from baseline to 6 months ($p < 0.001$) but thereafter declined up to 60 months ($P < 0.001$) towards baseline levels. Psychological variables affecting decreased SEF were poorer body image and increased HADS depression and anxiety. Age greatly impacted SEF with patients ≥ 50 years (proxy for post-menopausal status) reporting significantly worse SEF compared to those aged < 50 ($p < 0.001$). There was a steady decrease of SEE over time from 0-60 months with similar variables affecting this change, except for HADS anxiety, which was not significant.

Conclusion: Although CT has an initial adverse effect, sexual functioning and enjoyment appear to be mainly affected by age and psychological variables over time. The observed associations with depression and body image warrant further investigation and results will be reported. Women should be informed of likely treatment effects and offered appropriate advice and support.

153

Poster

Factors affecting body image concerns in early breast cancer

P. Hopwood¹, J. Mills², G. Sumo², J. Bliss². ¹Christie Hospital NHS Trust, Psycho-Oncology, Manchester, United Kingdom; ²The Institute of Cancer Research, Clinical Trials & Statistics Unit, Sutton, UK

Introduction: To explore the contribution of age, clinical and psychological factors on body image concerns, in women with early breast cancer treated in the START trial. This is a UK multicentre randomised trial of adjuvant radiotherapy in which quality of life will be an important secondary endpoint.

Methods: Women participating in the quality of life (QL) sub-study completed the 10-item Body Image Scale (BIS) and 14-item HADS, together with other standardised QOL measures, at baseline (after surgery and adjuvant chemotherapy but before radiotherapy) and at 6, 12, and 24 and 60 months follow-up. At baseline, the independent effects of age, clinical factors (time from surgery, type of surgery, chemotherapy, endocrine therapy), depression and anxiety were identified using multiple regression analysis. Change over time was tested using the Generalised Estimating Equations model.

Results: 2181 (99%) women completed baseline QL questionnaires, (mean age 56.9 years, range 26-87). 17.1% women had mastectomy, 82.9% underwent conservative surgery; median time from surgery was 8.0 weeks (IQR 5.6-19.6). One third of patients received adjuvant chemotherapy (CT). 75% women reported BIS concerns of any severity at baseline; the most prevalent body image items rated as 'quite a bit' or 'very much' were '... feeling less physically attractive', '... feeling less sexually attractive', '... feeling less feminine' and '... dissatisfied with your body'. Significantly worse BIS summary scores ($p < 0.001$) at baseline were found for women of younger age, having mastectomy, and/or receiving chemotherapy. BIS scores improved significantly from baseline to 1 year ($p < 0.001$) and were stable from 1-5 years ($p = NS$). There was no apparent negative effect on BIS scores from radiotherapy or endocrine therapy. From 0-12 months, poorer body image was predicted by age, having mastectomy, receiving chemotherapy, and greater anxiety and depression; these factors also predicted the most prevalent body image concerns. CT had no further effect from 12-60 months but the other factors remained.

Conclusions: Overall body image concerns improve over time and whilst the impact of CT remits after one year, the negative effects of age, mastectomy, anxiety and depression persist. A subgroup of patients at risk of body image disturbance can thus be identified. Neither radiotherapy nor endocrine therapy appear to have an influence on body image scores.

154

Poster

Patients' views of distress and interference with daily activities due to side effects from chemotherapy for early breast cancer: the TACT (Taxotere as Adjuvant ChemoTherapy) trial experience

P. Hopwood¹, D. Lawrence², D. Cameron³, P. Ellis⁴, L. Foster⁵, E. Hall², L. Johnston², S. Russell⁶, J. Bliss². On behalf of the TACT Trial Management Group. ¹Christie Hospital NHS Trust, Manchester, United Kingdom; ²The Institute of Cancer Research, Clinical Trials & Statistics Unit (ICR-CTSU), London, United Kingdom; ³Western General Hospital, Edinburgh, United Kingdom; ⁴Guy's & St Thomas' Hospital, London, United Kingdom; ⁵ISD Cancer Clinical Trials Team, Edinburgh, United Kingdom

Introduction: 4162 women with early breast cancer were randomised to receive adjuvant chemotherapy (CT) in the TACT trial (FECx4 followed by taxotere x4; (FEC-T)) vs FECx8 or epirubicin x4 + CMF x4 (E-CMF)) in which Quality of Life (QL) is an important secondary endpoint. This analysis describes the patient experience of chemotherapy side effects from treatment, in terms of distress and interference with activities, rather than just severity.

Methods: A protocol specific measure of 15 toxicities in the form of a daily diary card (not reported) and two additional questions, relating to *distress due to side effects* and extent of *interference in daily activities* from side effects was requested from all patients in the QL study. Questions were completed during CT (cycles 1, 5, and 8) and at 9, 12, 18 & 24 months. Patients rated *distress* and *interference* for each toxicity as 'not at all', 'a little', 'quite a bit', 'very much'. Toxicities rated as *distressing* or *interfering* with day to day activities (quite a bit/very much) by $>10\%$ patients at each time point were collated.

Results: Toxicity questions were completed by 455, 468, 410, 667, 645, 604 & 576 patients at cycle 1, 5 & 8 and at 9, 12, 18 & 24 months respectively. In cycle 1, *distressing* effects were nausea, vomiting, tiredness and constipation, reported by 30.4%, 20.1%, 30% and 13% patients respectively. Nausea, vomiting and tiredness also *interfered* with daily activities in similar proportions of patients. During successive cycles, most (12/15) symptoms were reported as *distressing*, with the exception of vomiting, skin problems, and lack of appetite. Symptoms most likely to *interfere* with activities on CT were nausea, tiredness, sore mouth, breathlessness, pain in muscles/joints and painful/gritty eyes, affecting 13%-54% patients, with greatest increases for breathlessness and painful muscles/joints. Following CT, only tiredness and pain in muscles/joints were reported as *interfering* by $>10\%$ patients but persisted up to 2 years from baseline. Over 10% of patients reported *distress* due to skin problems, tingling hands/feet, swollen hands/feet, nail changes, tiredness and painful muscles/joints at some point following treatment, with the latter two persisting for up to 2 years.

Conclusion: Most CT side effects cause more distress than interference with daily activities. Whilst most functional effects reduce over time, distress may persist for up to 2 years post CT and warrants more attention from treating teams.

155

Poster

The psychological impact of regular surveillance in women at increased risk for hereditary breast cancer

S. van Dooren¹, C. Seynaeve², C.C.M. Bartels², A. Rijsbergen³, H.J. Duivenvoorden¹, J. Passchier¹, J.G.M. Klijn², A. Tibben^{1,4}. ¹Erasmus MC, medical psychology and psychotherapy, Rotterdam, The Netherlands; ²Erasmus MC, Medical and Surgical Oncology, Rotterdam, the Netherlands; ³Erasmus MC, dept. of Public Health, Rotterdam, the Netherlands; ⁴LUMC, Centre of Human and Clinical Genetics, Leiden, the Netherlands

Aim To identify women at risk for hereditary breast cancer adhering to regular surveillance who experience increased distress.

Methods 357 High-risk women (cumulative life time risk $>15\%$) participating in the psychological sub-study of the national MRISC-study, regarding the evaluation of MRI-screening in high-risk women were studied. Questionnaires, administered before and after two surveillance-visits (C1, C2), assessed the psychological impact of adhering to the surveillance programme (annual MRI and mammography, biannual clinical breast examination). Outcome variables were BC specific distress (Impacts of Event Scale) and general distress (Hospital Anxiety and Depression Scale). With regression analyses and Structural Equation Modelling subgroups of women who were vulnerable for psychological distress and the courses of distress around surveillance were explored.

Results At baseline (i.e. two months before the surveillance visit) three factors were found to be associated with higher levels of BC specific distress: excessive breast self examination while being younger than 40 years of age; risk overestimation (cognitive and affective), and being